Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown
notable progress. An increasing number of aspects of the immune system are being …

Importance Observational (nonexperimental) studies that aim to emulate a randomized trial
(ie, the target trial) are increasingly informing medical and policy decision-making, but it is …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds
with high affinity to interleukin‐13, effectively reduces moderate‐to‐severe atopic dermatitis …

Background Tralokinumab is a fully human monoclonal antibody that neutralizes the activity
of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including …

Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that most frequently occurs in
children, but it can also affect adults. Even though most AD cases can be managed with …

The last decade has seen an unprecedented pace of change, particularly of clinical
research in atopic dermatitis (AD). This review summarizes some key discoveries. Over the …

Importance Allergic history in individuals with confirmed anaphylaxis to a messenger RNA
(mRNA) COVID-19 vaccine is common. However, the risk factors for allergy symptoms after …

Background Dupilumab‐associated ocular surface disease (DAOSD) is frequently reported
as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to …

Atopic dermatitis (AD) is a common inflammatory skin disease characterised by itch and is
responsible for significant reduction in quality of life. While AD primarily arises in those …